MX378515B - Aminotriazolopiridinas como inhibidores de cinasa. - Google Patents

Aminotriazolopiridinas como inhibidores de cinasa.

Info

Publication number
MX378515B
MX378515B MX2019009555A MX2019009555A MX378515B MX 378515 B MX378515 B MX 378515B MX 2019009555 A MX2019009555 A MX 2019009555A MX 2019009555 A MX2019009555 A MX 2019009555A MX 378515 B MX378515 B MX 378515B
Authority
MX
Mexico
Prior art keywords
aminotriazolopyridines
kinase inhibitors
ripk1
diastereomers
prodrugs
Prior art date
Application number
MX2019009555A
Other languages
English (en)
Spanish (es)
Other versions
MX2019009555A (es
Inventor
Amy C Hart
Carolyn Diane Dzierba
Guanglin Luo
Jianliang Shi
Jie Chen
John E Macor
Junqing Guo
Michael E Mertzman
Murugaiah Subbaiah Murugaiah Andappan
Scott Hunter Watterson
Sing-Yuen Sit
Steven H Spergel
William J Pitts
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2019009555A publication Critical patent/MX2019009555A/es
Publication of MX378515B publication Critical patent/MX378515B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2019009555A 2017-02-13 2018-02-12 Aminotriazolopiridinas como inhibidores de cinasa. MX378515B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13
PCT/US2018/017755 WO2018148626A1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2019009555A MX2019009555A (es) 2019-10-02
MX378515B true MX378515B (es) 2025-03-11

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009555A MX378515B (es) 2017-02-13 2018-02-12 Aminotriazolopiridinas como inhibidores de cinasa.

Country Status (25)

Country Link
US (3) US10913738B2 (enExample)
EP (1) EP3580220B1 (enExample)
JP (1) JP7097373B2 (enExample)
KR (1) KR102549952B1 (enExample)
CN (1) CN110520423B (enExample)
AU (1) AU2018217488B2 (enExample)
BR (1) BR112019016635A2 (enExample)
CA (1) CA3053484A1 (enExample)
CY (1) CY1124978T1 (enExample)
DK (1) DK3580220T3 (enExample)
EA (1) EA039808B1 (enExample)
ES (1) ES2902676T3 (enExample)
HR (1) HRP20212000T1 (enExample)
HU (1) HUE057801T2 (enExample)
IL (1) IL268614B (enExample)
LT (1) LT3580220T (enExample)
MA (1) MA47460A (enExample)
MX (1) MX378515B (enExample)
PL (1) PL3580220T3 (enExample)
PT (1) PT3580220T (enExample)
RS (1) RS62801B1 (enExample)
SG (1) SG11201907335UA (enExample)
SI (1) SI3580220T1 (enExample)
SM (1) SMT202200001T1 (enExample)
WO (1) WO2018148626A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3580220T1 (sl) * 2017-02-13 2022-01-31 Bristol-Myers Squibb Company Aminotriazolopiridini kot kinazni inhibitorji
SG11202003824PA (en) * 2017-10-30 2020-05-28 Bristol Myers Squibb Co Aminoimidazopyridazines as kinase inhibitors
EA202091777A1 (ru) 2018-01-26 2020-10-14 Бристол-Маерс Сквибб Компани Аминопирролотриазины в качестве ингибиторов киназы
SG11202100137TA (en) * 2018-07-09 2021-02-25 Lieber Institute Inc PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
AU2019301628C1 (en) 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
US12084426B2 (en) 2018-09-13 2024-09-10 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
JP7599411B2 (ja) 2018-09-13 2024-12-13 ブリストル-マイヤーズ スクイブ カンパニー 受容体相互作用タンパク質キナーゼ1阻害剤(ripk1)としての1h-インダゾールカルボキサミド
AU2020210455B2 (en) * 2019-01-25 2023-02-02 Beijing Scitech-Mq Pharmaceuticals Limited Acylamino bridged heterocyclic compound, and composition and application thereof
CN113508109B (zh) * 2019-03-22 2023-02-10 劲方医药科技(上海)有限公司 取代的杂环酰胺类化合物,其制法与医药上的用途
MX2022003769A (es) 2019-10-03 2022-04-20 Bristol Myers Squibb Co Indazol carboxamidas como inhibidores de cinasas.
WO2021160109A1 (zh) * 2020-02-13 2021-08-19 劲方医药科技(上海)有限公司 二氢萘啶酮类化合物,其制法与医药上的用途
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
EP4301744A1 (en) 2021-08-10 2024-01-10 AbbVie Inc. Nicotinamide ripk1 inhibitors
WO2023174374A1 (zh) 2022-03-16 2023-09-21 江苏恒瑞医药股份有限公司 稠杂环类化合物、其制备方法及其在医药上的应用
CN114989079B (zh) * 2022-06-21 2023-06-23 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025072395A1 (en) * 2023-09-27 2025-04-03 Bristol-Myers Squibb Company Triazolopyridinyl compounds as kinase inhibitors
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
PY2501648A (es) 2024-01-12 2025-10-31 Syngenta Crop Protection Ag Nuevos compuestos de carboxamida
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004702A1 (en) 2004-06-25 2006-01-12 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
WO2007117465A2 (en) * 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
EP2222674B8 (en) 2007-11-27 2016-01-06 Cellzome Limited Amino triazoles as pi3k inhibitors
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
EP2393813B1 (en) 2009-02-04 2013-07-31 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
CN105246891A (zh) 2013-06-10 2016-01-13 拜耳制药股份公司 用于治疗癌症的新化合物
BR112017003546A2 (pt) 2014-08-21 2017-12-05 Glaxosmithkline Ip Dev Ltd amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
CN108349970B (zh) 2015-11-05 2021-03-05 住友化学株式会社 稠合杂环化合物
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
CN110198942B (zh) 2017-01-24 2022-04-15 住友化学株式会社 稠合杂环化合物及含有其的组合物
SI3580220T1 (sl) * 2017-02-13 2022-01-31 Bristol-Myers Squibb Company Aminotriazolopiridini kot kinazni inhibitorji
SG11202003824PA (en) 2017-10-30 2020-05-28 Bristol Myers Squibb Co Aminoimidazopyridazines as kinase inhibitors
EA202091777A1 (ru) 2018-01-26 2020-10-14 Бристол-Маерс Сквибб Компани Аминопирролотриазины в качестве ингибиторов киназы
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
PL3580220T3 (pl) 2022-02-07
HRP20212000T1 (hr) 2022-04-01
US20220315580A1 (en) 2022-10-06
ES2902676T3 (es) 2022-03-29
WO2018148626A1 (en) 2018-08-16
JP7097373B2 (ja) 2022-07-07
CY1124978T1 (el) 2023-01-05
US10913738B2 (en) 2021-02-09
RS62801B1 (sr) 2022-02-28
CA3053484A1 (en) 2018-08-16
JP2020507582A (ja) 2020-03-12
AU2018217488B2 (en) 2021-09-23
SI3580220T1 (sl) 2022-01-31
MA47460A (fr) 2019-12-18
CN110520423A (zh) 2019-11-29
SG11201907335UA (en) 2019-09-27
EA039808B1 (ru) 2022-03-16
SMT202200001T1 (it) 2022-03-21
AU2018217488A1 (en) 2019-10-03
KR20190117006A (ko) 2019-10-15
IL268614B (en) 2021-12-01
CN110520423B (zh) 2022-08-23
US20250074909A1 (en) 2025-03-06
PT3580220T (pt) 2022-01-03
BR112019016635A2 (pt) 2020-04-07
EP3580220B1 (en) 2021-11-17
US20190389859A1 (en) 2019-12-26
EP3580220A1 (en) 2019-12-18
LT3580220T (lt) 2021-12-27
HUE057801T2 (hu) 2022-06-28
DK3580220T3 (da) 2022-01-10
KR102549952B1 (ko) 2023-06-29
US12157733B2 (en) 2024-12-03
EA201991915A1 (ru) 2019-12-30
MX2019009555A (es) 2019-10-02
IL268614A (en) 2019-10-31

Similar Documents

Publication Publication Date Title
MX2019009555A (es) Aminotriazolopiridinas como inhibidores de cinasa.
CL2021002519A1 (es) Compuestos de diazina-amida activos como pesticidas.
PY1986700A (es) Compuestos de azol-amida pesticidamente activos
UY37900A (es) Nuevos derivados de rapamicina
PY1974248A (es) Compuestos de azol-amida pesticidamente activos
PY1974629A (es) Compuestos de azol-amida pesticidamente activos
CY1124984T1 (el) Αμινοïμιδαζοπυριδινες ως αναστολεις κινασων
PY1991119A (es) Compuestos de azol-amida pesticidamente activos
PY1950234A (es) Compuestos de azol-amida pesticidamente activos
CR20170392A (es) Compuestos bicíclicos de sulfonamida cetona
CR20120410A (es) Pirrolidina-2-carboxamidas sustituidas
UY35630A (es) Carboxamidas primarias como inhibidores de btk
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CR20110099A (es) Pirrolidina-2-carboxamidas sustituidas
MX2019010602A (es) Inhibidores de cdk.
UY36629A (es) Indazolonas como moduladores de la señalización de tnf
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY36910A (es) Benzamidas de bis isoxazolinas como compuestos insecticidas
MX2023004492A (es) Compuestos de triazolopiridinilo como inhibidores de cinasas.
EA202190759A1 (ru) Индазолкарбоксамиды в качестве ингибиторов киназ
EA202190718A1 (ru) Индазолкарбоксамиды в качестве ингибиторов киназ
MX2022003769A (es) Indazol carboxamidas como inhibidores de cinasas.
CO2018004213A2 (es) Compuesto piranodipiridínico
UY36628A (es) Indazolonas como moduladores de la señalización de tnf
CL2015003037A1 (es) Derivados de triazina